Life Sciences Partners (LSP)

https://www.lspvc.com

LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. With offices in Amsterdam, Munich, and Boston, LSP currently has the possibility to invest from three funds, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. *

	Start	1988-01-01 existent
	End	2022-03-01 renamed
	Group	EQT (Wallenberg family) (Group)
	Today	EQT Life Sciences
	Successor	EQT Life Sciences
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Kleijwegt, Martijn (Life Sciences Partners 200612 Managing Partner)
	Person 2	Portwich, Anne (Life Sciences Partners 201510 Partner)

	Region	Amsterdam
	Country	Netherlands
	Street	9 Johannes Vermeerplain
	City	1071 DV Amsterdam
	Tel	+31-20-664-5500
		Address record changed: 2021-01-20

Basic data	Employees	B: 11 to 50 (2021-11-10)
	Currency	EUR
	Annual sales	1,000,000,000 (capital raised to date (2017) 2017-03-08)

		* Document for »About Section«: Life Sciences Partners (LSP). (1/20/21). "Press Release: LSP Leads EUR 21 Million Series B Funding Round in Neurent Medical". Amsterdam.

		Record changed: 2024-03-19